Johnson & Johnson
NYSE:JNJ
Johnson & Johnson
NYSE:JNJ
Price:
242.11
USD
1.2%
Market Cap:
$583.5B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Johnson & Johnson
NYSE:JNJ
|
US |
Multiples-Based Value
The Multiples-Based Value of one
JNJ
stock under the Base Case scenario is
172.93
USD.
Compared to the current market price of 242.11 USD,
Johnson & Johnson
is
Overvalued by 29%.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
JNJ
Multiples-Based Value
Base Case
172.93
USD
Overvaluation 29%
Multiples Across Competitors
JNJ Competitors Multiples
Johnson & Johnson Competitors
Johnson & Johnson Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
576.1B USD | 6.2 | 21.8 | 15.1 | 18.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
847.5B USD | 12.9 | 40.7 | 27.5 | 29.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.5 | 12.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.3B USD | 4.6 | 16.3 | 10.1 | 12.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.3B CHF | 5.2 | 21.1 | 13 | 16.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.5B GBP | 5.1 | 29.1 | 16.1 | 22.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.3 | 9.8 | 7.3 | 8.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.8B USD | 2.5 | 19.9 | 7.7 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.6B USD | 2.5 | 16.8 | 7.1 | 8.7 | |
| FR |
|
Sanofi SA
PAR:SAN
|
99.1B EUR | 2.1 | 12.7 | 10.6 | 10.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
